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Background: Warfarin reduces stroke in atrial fibrillation (AF) but causes bleeding. In the 18,113 patient RE-LY randomised trial, dabigatran 150 
mg bid reduced stroke and intracranial bleeding, and dabigatran 110 mg bid reduced major bleeding with a similar rate of stroke, compared with 
warfarin. Advanced age increases the risks of stroke and of bleeding in AF and is also associated with decreased renal function. D is 80% renally 
excreted. The objective of this analysis was to explore the effects of age and renal function on risks of stroke and major bleeding with dabigatran 
versus warfarin.
Methods and Results: The RE-LY trial included 7258 patients aged ≥75 years and 3,505 patients with a CrCl of 30 to 50 ml/min. For the 
primary efficacy outcome of stroke or systemic embolism, there was no significant interaction between age or baseline renal function and dabigatran 
treatment. Rates of major bleeding increased with age and there was a significant interaction between age and treatment (p<0.001 for each dose 
of dabigatran vs warfarin) that attenuated the benefits of dabigatran with increasing age. For patients aged <65, both doses of dabigatran reduced 
the risk of major bleeding compared to warfarin (0.71, 0.79 and 2.27 %/year for dabigatran 110, 150 and warfarin, respectively), but in patients 
aged >75, the rates of major bleeding were similar or higher with dabigatran compared with warfarin (4.17, 4.81 and 4.09 %/year on dabigatran 
110, 150 and warfarin, respectively). An interaction between renal function and treatment was no longer evident after adjustment for age. There was 
no interaction between either age or renal function and the benefits of dabigatran versus warfarin in reducing hemorrhagic stroke, with hemorrhagic 
stroke rates in patients >75 years of 0.20, 0.14 and 0.47%/year for dabigatran 110, 150 and warfarin respectively (p<0.05 for both D doses versus 
W).
Conclusions: The benefit of dabigatran versus warfarin for stroke prevention is independent of age and renal function. The benefit of dabigatran 
versus warfarin in reducing extracranial bleeding is significantly attenuated with increasing age, but the reduction in hemorrhagic stroke is not.
